Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29770078 | 0.98 | CRBN (0.34) | CRBNNEK2 | |
| Hydrochloric Acid SCHEMBL19520634 | 0.98 | CRBN (0.34) | CRBNNEK2 | |
| SCHEMBL21315419 | 0.87 | CRBN (0.46) | CRBN | |
| SCHEMBL21274164 | 0.87 | CRBN (0.46) | CRBN | |
| SCHEMBL8603859 | 0.83 | — | — | |
| SCHEMBL31521219 | 0.79 | CRBN (0.36) | CRBNNEK2 | |
| SCHEMBL19745505 | 0.78 | — | — | |
| SCHEMBL22447830 | 0.78 | IDO1 (0.35) | — | |
| SCHEMBL16112511 | 0.78 | IDO1 (0.35) | — | |
| SCHEMBL11055887 | 0.78 | IDO1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| CN-119977980-A | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-05-13 | — | — | CN | claimed |
| CN-110177776-B | Novel modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-02-28 | — | — | CN | claimed |
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | claimed |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | DART NEUROSCIENCE, LLC (US) | 2023-06-27 | — | — | US | claimed |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC | 2022-08-25 | — | — | US | claimed |
| EP-3652180-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | Dart NeuroScience LLC (US) | 2020-05-20 | — | — | EP | claimed |
| CN-111094293-A | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | 达特神经科学有限公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | claimed |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260048059-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANC | WIRTH KLAUS (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4572766-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
| WO-2009124167-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CRBN 4520/4885NEK2 3281/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CRBN 4520/4885NEK2 3281/4885 |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | HTR2A, HTR5A, HTR1A | CRBN 4733/4885NEK2 1356/4885 |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | PDE7A, PDE7B, PDE8B | CRBN 2063/4885NEK2 802/4885 |
| US-20260048059-A1 | USE OF SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANC | FANCF, EPAS1, PDE4C | CRBN 3760/4885NEK2 1881/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | CRBN 1915/4885NEK2 859/4885 |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | CRBN 3073/4885NEK2 269/4885 |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | PDE7A, PDE7B, PDE8B | CRBN 2063/4885NEK2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.